Free Trial

Teladoc Health (TDOC) Financials

Teladoc Health logo
$6.82 -0.08 (-1.09%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$6.85 +0.03 (+0.42%)
As of 04/17/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Teladoc Health

Annual Income Statements for Teladoc Health

This table shows Teladoc Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-17 -58 -74 -107 -97 -99 -485 -429 -13,660 -220 -1,001
Consolidated Net Income / (Loss)
-17 -58 -74 -107 -97 -99 -485 -429 -13,660 -220 -1,001
Net Income / (Loss) Continuing Operations
-17 -58 -74 -107 -97 -99 -485 -429 -13,660 -220 -1,001
Total Pre-Tax Income
-17 -58 -74 -107 -97 -109 -576 -385 -13,663 -220 -994
Total Operating Income
-15 -56 -63 -75 -71 -80 -506 -266 -13,653 -249 -1,021
Total Gross Profit
34 56 91 172 289 369 703 1,382 1,663 1,842 1,818
Total Revenue
44 77 123 233 418 553 1,094 2,033 2,407 2,602 2,570
Operating Revenue
44 77 123 233 418 553 1,094 2,033 2,407 2,602 2,570
Total Cost of Revenue
9.93 21 32 62 129 184 391 650 744 760 751
Operating Cost of Revenue
9.93 21 32 62 129 184 391 650 744 760 751
Total Operating Expenses
49 112 154 247 360 449 1,210 1,648 15,316 2,091 2,839
Selling, General & Admin Expense
29 61 75 118 176 229 661 689 677 678 640
Marketing Expense
7.66 20 35 58 85 110 226 417 624 689 706
Research & Development Expense
7.57 14 22 34 54 65 165 312 334 349 307
Depreciation Expense
2.32 4.86 8.27 19 36 39 69 8.94 11 11 10
Amortization Expense
- - - - - - - 195 245 326 363
Impairment Charge
- - - - - - 0.00 0.00 13,403 0.00 790
Restructuring Charge
0.20 0.55 6.96 13 10 6.62 88 27 23 38 22
Total Other Income / (Expense), net
-1.50 -2.20 -11 -32 -26 -29 -70 -119 -10 29 27
Interest Expense
1.50 2.20 2.59 17 26 29 69 125 22 22 24
Interest & Investment Income
- - - - - - - 0.78 13 47 57
Other Income / (Expense), net
- - -8.45 -14 - 0.34 -0.55 5.09 -0.86 4.45 -6.04
Income Tax Expense
0.39 0.04 0.51 -0.23 0.12 -11 -91 44 -3.81 0.76 7.59
Basic Earnings per Share
($10.25) ($2.91) ($1.75) ($1.93) ($1.47) ($1.38) ($5.36) ($2.73) ($84.60) ($1.34) ($5.87)
Weighted Average Basic Shares Outstanding
1.96M 19.92M 42.33M 55.43M 65.84M 71.84M 90.51M 156.94M 161.46M 164.58M 170.56M
Diluted Earnings per Share
($10.25) ($2.91) ($1.75) ($1.93) ($1.47) ($1.38) ($5.36) ($2.73) ($84.60) ($1.34) ($5.87)
Weighted Average Diluted Shares Outstanding
1.96M 19.92M 42.33M 55.43M 65.84M 71.84M 90.51M 156.94M 161.46M 164.58M 170.56M
Weighted Average Basic & Diluted Shares Outstanding
1.96M 19.92M 42.33M 55.43M 65.84M 71.84M 90.51M 160.33M 162.62M 167.04M 173.67M

Quarterly Income Statements for Teladoc Health

This table shows Teladoc Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-73 -3,810 -69 -65 -57 -29 -82 -838 -33 -48
Consolidated Net Income / (Loss)
-73 -3,810 -69 -65 -57 -29 -82 -838 -33 -48
Net Income / (Loss) Continuing Operations
-73 -3,810 -69 -65 -57 -29 -82 -838 -33 -48
Total Pre-Tax Income
-75 -3,812 -69 -66 -60 -25 -79 -834 -32 -48
Total Operating Income
-72 -3,816 -77 -72 -65 -35 -87 -841 -44 -48
Total Gross Profit
426 449 439 462 474 467 452 454 461 452
Total Revenue
611 638 629 652 660 661 646 642 641 640
Operating Revenue
611 638 629 652 660 661 646 642 641 640
Total Cost of Revenue
186 189 190 191 186 193 195 188 180 189
Operating Cost of Revenue
186 189 190 191 186 193 195 188 180 189
Total Operating Expenses
498 4,264 516 534 539 502 539 1,296 505 500
Selling, General & Admin Expense
167 176 169 179 168 162 166 160 162 153
Marketing Expense
179 146 177 179 186 147 183 170 177 175
Research & Development Expense
85 83 87 87 84 90 81 77 72 77
Depreciation Expense
62 -169 2.92 2.95 2.47 2.79 2.83 1.70 2.67 2.98
Amortization Expense
- - 67 73 92 95 95 95 87 87
Restructuring Charge
5.27 10 14 13 6.24 5.16 10 1.96 4.04 6.06
Total Other Income / (Expense), net
-2.92 3.64 8.56 5.52 5.17 9.71 7.92 13 12 -5.60
Interest & Investment Income
4.80 - 8.91 12 13 14 14 14 15 14
Other Income / (Expense), net
-1.57 1.75 4.91 -0.21 -1.79 1.54 -0.37 -0.56 2.24 -7.34
Income Tax Expense
-1.17 -1.84 0.68 -0.95 -2.48 3.52 2.69 3.88 0.78 0.24
Basic Earnings per Share
($0.45) ($23.35) ($0.42) ($0.40) ($0.35) ($0.17) ($0.49) ($4.92) ($0.19) ($0.27)
Weighted Average Basic Shares Outstanding
161.73M 161.46M 162.92M 164.17M 165.12M 164.58M 167.73M 170.23M 171.50M 170.56M
Diluted Earnings per Share
($0.45) ($23.35) ($0.42) ($0.40) ($0.35) ($0.17) ($0.49) ($4.92) ($0.19) ($0.27)
Weighted Average Diluted Shares Outstanding
161.73M 161.46M 162.92M 164.17M 165.12M 164.58M 167.73M 170.23M 171.50M 170.56M
Weighted Average Basic & Diluted Shares Outstanding
161.93M 162.62M 163.67M 164.95M 165.56M 167.04M 169.59M 171.22M 172.17M 173.67M

Annual Cash Flow Statements for Teladoc Health

This table details how cash moves in and out of Teladoc Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
43 8.63 -5.05 -7.39 383 90 215 162 28 205 178
Net Cash From Operating Activities
-11 -47 -52 -34 -4.86 30 -54 194 189 350 294
Net Cash From Continuing Operating Activities
-11 -47 -52 -34 -4.86 30 -54 194 189 350 294
Net Income / (Loss) Continuing Operations
-17 -58 -74 -107 -97 -99 -485 -429 -13,660 -220 -1,001
Consolidated Net Income / (Loss)
-17 -58 -74 -107 -97 -99 -485 -429 -13,660 -220 -1,001
Depreciation Expense
2.32 4.86 8.27 19 36 39 71 12 11 11 10
Amortization Expense
- - 7.72 14 0.00 6.00 6.90 207 256 338 373
Non-Cash Adjustments To Reconcile Net Income
1.95 6.37 10 39 60 96 534 405 13,637 212 950
Changes in Operating Assets and Liabilities, net
1.41 -0.39 -4.04 0.41 -3.38 -12 -181 -2.19 -56 9.74 -37
Net Cash From Investing Activities
-16 -108 26 -448 -257 25 -591 -73 -168 -156 -124
Net Cash From Continuing Investing Activities
-16 -108 26 -448 -257 25 -591 -73 -168 -156 -124
Purchase of Property, Plant & Equipment
-1.07 -6.28 -2.11 -2.63 -4.01 -3.51 -26 -64 -173 -156 -124
Sale and/or Maturity of Investments
- 20 111 86 84 47 2.50 61 2.51 0.00 0.00
Other Investing Activities, net
- - - - - 0.00 0.00 8.72 2.51 0.00 0.00
Net Cash From Financing Activities
70 164 21 475 646 35 859 41 6.50 11 8.31
Net Cash From Continuing Financing Activities
70 164 21 475 646 35 859 41 6.50 11 8.31
Repayment of Debt
- -6.33 -17 -226 0.00 0.00 -34 -5.07 -5.89 -0.28 -0.00
Issuance of Common Equity
- 163 0.25 261 333 3.38 4.72 17 6.50 9.65 4.75
Other Financing Activities, net
0.75 0.43 2.60 177 33 32 117 29 5.88 1.48 3.57
Cash Interest Paid
1.19 2.00 2.39 9.45 10 12 15 19 17 17 17
Cash Income Taxes Paid
- - - 0.14 0.44 1.31 1.32 3.97 2.51 7.24 8.95

Quarterly Cash Flow Statements for Teladoc Health

This table details how cash moves in and out of Teladoc Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
22 16 -29 69 73 92 -25 65 80 58
Net Cash From Operating Activities
63 66 13 101 106 130 8.92 89 110 86
Net Cash From Continuing Operating Activities
63 66 13 101 106 130 8.92 89 110 86
Net Income / (Loss) Continuing Operations
-73 -3,810 -69 -65 -57 -29 -82 -838 -33 -48
Consolidated Net Income / (Loss)
-73 -3,810 -69 -65 -57 -29 -82 -838 -33 -48
Depreciation Expense
63 -171 2.92 2.95 2.47 2.79 2.83 1.70 2.67 2.98
Amortization Expense
2.73 247 70 75 94 98 98 97 89 89
Non-Cash Adjustments To Reconcile Net Income
63 3,825 53 59 57 43 44 834 38 34
Changes in Operating Assets and Liabilities, net
7.88 -26 -44 29 8.80 16 -54 -6.62 14 8.99
Net Cash From Investing Activities
-41 -54 -46 -37 -38 -37 -36 -28 -31 -30
Net Cash From Continuing Investing Activities
-41 -54 -46 -37 -38 -37 -36 -28 -31 -30
Purchase of Property, Plant & Equipment
-43 -54 -46 -37 -38 -37 -36 -28 -31 -30
Net Cash From Financing Activities
0.63 4.38 3.35 4.21 5.07 -1.78 1.75 3.81 0.70 2.06
Net Cash From Continuing Financing Activities
0.63 4.38 3.35 4.21 5.07 -1.78 1.75 3.81 0.70 2.06
Issuance of Common Equity
1.41 3.12 2.73 2.70 3.16 1.05 1.52 1.28 0.92 1.03
Other Financing Activities, net
1.21 -0.36 0.79 1.34 1.91 -2.55 0.24 2.52 -0.23 1.03
Cash Interest Paid
0.02 8.67 0.19 8.48 0.01 8.74 0.00 8.66 - 8.66
Cash Income Taxes Paid
0.34 1.61 0.35 0.44 5.53 0.92 -0.25 4.86 2.62 1.71

Annual Balance Sheets for Teladoc Health

This table presents Teladoc Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
92 230 304 824 1,529 1,603 17,755 17,735 4,345 4,392 3,517
Total Current Assets
54 152 83 156 533 588 1,060 1,225 1,315 1,489 1,664
Cash & Equivalents
46 55 50 43 424 514 733 893 918 1,124 1,298
Accounts Receivable
6.84 12 14 27 44 57 169 169 211 217 214
Inventories, net
- - - - - 0.00 56 73 56 30 38
Prepaid Expenses
0.97 2.10 3.10 6.84 11 14 47 87 130 118 113
Plant, Property, & Equipment, net
1.07 6.26 7.48 8.96 10 10 29 27 30 32 29
Total Noncurrent Assets
36 72 213 659 986 1,005 16,667 16,482 3,000 2,871 1,823
Goodwill
28 56 188 499 737 746 14,581 14,504 1,073 1,073 283
Intangible Assets
7.53 15 25 160 247 225 2,021 1,910 1,837 1,678 1,431
Other Noncurrent Operating Assets
0.30 0.29 0.42 0.86 1.40 33 65 67 90 120 109
Total Liabilities & Shareholders' Equity
92 230 304 824 1,529 1,603 17,755 17,735 4,345 4,392 3,517
Total Liabilities
39 51 73 265 516 589 1,871 1,680 2,038 2,066 2,025
Total Current Liabilities
10 18 21 40 62 90 333 331 400 421 942
Short-Term Debt
0.83 1.25 2.00 - - 0.00 43 - - 0.00 551
Accounts Payable
2.21 2.21 2.24 3.88 7.77 9.08 46 47 48 44 33
Accrued Expenses
3.92 8.20 7.98 19 27 34 84 103 169 179 202
Current Deferred Revenue
- - - - - 12 52 76 102 96 79
Current Employee Benefit Liabilities
3.36 6.33 8.86 17 28 34 95 92 82 103 76
Total Noncurrent Liabilities
28 33 52 225 453 499 1,539 1,349 1,638 1,646 1,084
Long-Term Debt
25 25 42 207 415 440 1,380 1,226 1,535 1,539 991
Capital Lease Obligations
- - - - - 25 43 - 38 43 32
Noncurrent Deferred Revenue
- - - - - 2.30 12 3.83 12 14 9.79
Noncurrent Deferred & Payable Income Tax Liabilities
0.48 1.19 1.69 13 32 22 102 76 51 49 50
Other Noncurrent Operating Liabilities
2.77 6.78 7.61 4.88 6.19 9.24 1.62 53 1.62 1.08 0.72
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-68 179 231 559 1,013 1,014 15,884 16,046 2,308 2,326 1,491
Total Preferred & Common Equity
-68 179 231 559 1,013 1,014 15,884 16,046 2,308 2,326 1,491
Total Common Equity
-68 179 231 559 1,013 1,014 15,884 16,046 2,308 2,326 1,491
Common Stock
4.96 309 436 866 1,435 1,539 16,858 17,473 17,359 17,592 17,759
Retained Earnings
-72 -131 -205 -312 -409 -508 -993 -1,421 -15,008 -15,229 -16,230
Accumulated Other Comprehensive Income / (Loss)
- -0.04 -0.00 4.09 -13 -17 19 -6.29 -43 -37 -38

Quarterly Balance Sheets for Teladoc Health

This table presents Teladoc Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
8,104 4,309 4,316 4,328 4,321 3,524 3,529
Total Current Assets
1,288 1,287 1,321 1,387 1,486 1,547 1,609
Cash & Equivalents
900 889 959 1,031 1,098 1,162 1,244
Accounts Receivable
202 216 215 206 214 218 212
Inventories, net
59 46 34 36 32 35 37
Prepaid Expenses
127 136 113 115 142 131 116
Plant, Property, & Equipment, net
27 30 30 33 30 29 28
Total Noncurrent Assets
6,789 2,993 2,965 2,908 2,805 1,948 1,892
Goodwill
4,846 1,073 1,073 1,073 1,073 283 283
Intangible Assets
1,854 1,816 1,784 1,728 1,614 1,547 1,497
Other Noncurrent Operating Assets
89 104 108 107 118 117 112
Total Liabilities & Shareholders' Equity
8,104 4,309 4,316 4,328 4,321 3,524 3,529
Total Liabilities
2,051 2,010 2,021 2,034 2,032 2,022 2,021
Total Current Liabilities
411 381 383 403 389 931 931
Short-Term Debt
- - - - - 551 551
Accounts Payable
71 39 16 26 38 56 38
Accrued Expenses
177 185 193 193 199 174 188
Current Deferred Revenue
90 96 107 99 101 95 88
Current Employee Benefit Liabilities
63 51 67 85 51 55 66
Total Noncurrent Liabilities
1,640 1,629 1,638 1,631 1,643 1,091 1,089
Long-Term Debt
1,534 1,536 1,537 1,538 1,540 990 991
Capital Lease Obligations
41 - 37 34 40 38 37
Noncurrent Deferred Revenue
11 4.12 14 13 15 12 10
Noncurrent Deferred & Payable Income Tax Liabilities
52 51 48 44 47 51 51
Other Noncurrent Operating Liabilities
1.63 46 1.74 1.69 1.02 1.01 0.74
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
6,053 2,291 2,295 2,294 2,289 1,502 1,508
Total Preferred & Common Equity
6,053 2,291 2,295 2,294 2,289 1,502 1,508
Total Common Equity
6,053 2,291 2,295 2,294 2,289 1,502 1,508
Common Stock
17,300 17,410 17,477 17,535 17,638 17,689 17,726
Retained Earnings
-11,198 -15,078 -15,143 -15,200 -15,311 -16,148 -16,181
Accumulated Other Comprehensive Income / (Loss)
-49 -41 -39 -42 -39 -39 -37

Annual Metrics and Ratios for Teladoc Health

This table displays calculated financial ratios and metrics derived from Teladoc Health's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
118.67% 77.78% 59.15% 89.42% 79.14% 32.40% 97.71% 85.81% 18.41% 8.13% -1.26%
EBITDA Growth
-150.83% -296.90% -8.27% -2.12% 37.38% 0.30% -1,120.21% 90.46% -32,611.72% 100.78% -715.68%
EBIT Growth
-158.14% -268.22% -27.49% -25.87% 20.85% -13.05% -532.92% 48.61% -5,140.62% 98.21% -320.68%
NOPAT Growth
-158.14% -268.22% -12.33% -20.31% 6.02% -13.53% -529.55% 47.55% -5,039.92% 98.18% -310.73%
Net Income Growth
-183.05% -240.55% -27.91% -43.88% 9.08% -1.83% -390.71% 11.61% -3,085.58% 98.39% -354.35%
EPS Growth
-27.33% 71.61% 39.86% -10.29% 23.83% 6.12% -288.41% 49.07% -2,998.90% 98.42% -338.06%
Operating Cash Flow Growth
-87.66% -315.36% -9.95% 33.61% 85.89% 714.59% -279.15% 462.52% -2.42% 84.91% -16.10%
Free Cash Flow Firm Growth
0.00% -71.18% -150.64% -162.45% 27.16% 80.44% -22,887.30% 100.01% 327,645.32% -99.87% 5,966.24%
Invested Capital Growth
0.00% 107.22% 209.46% 207.40% 47.41% 1.38% 1,621.02% -1.13% -81.91% -6.04% -36.53%
Revenue Q/Q Growth
0.00% 0.00% 13.62% 20.53% 12.25% 6.50% 26.16% 9.18% 3.59% 0.88% -0.77%
EBITDA Q/Q Growth
0.00% 0.00% 2.53% -16.52% 20.12% 10.51% -2,004.20% 91.64% -38.96% 102.83% -5.54%
EBIT Q/Q Growth
0.00% 0.00% -11.51% -39.73% 8.67% 3.13% -698.33% 61.51% -38.17% 93.93% -2.19%
NOPAT Q/Q Growth
0.00% 0.00% 1.75% -17.68% 8.67% 2.72% -697.48% 61.09% -38.20% 93.83% -1.30%
Net Income Q/Q Growth
0.00% 0.00% 1.00% -39.29% 16.73% 5.57% -340.18% 47.18% -38.53% 94.49% -1.99%
EPS Q/Q Growth
0.00% 0.00% -119.23% -33.10% 23.83% 5.48% -274.83% 60.38% -38.05% 94.54% -1.73%
Operating Cash Flow Q/Q Growth
0.00% -22.04% 9.22% 0.75% 66.74% 110.00% -167.27% 4,769.96% -8.53% 22.60% -13.08%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -1.88% 4.84% -126.74% -1,347.82% 100.01% 39.11% -99.54% 4.86%
Invested Capital Q/Q Growth
0.00% 0.00% -1.10% -0.20% -1.52% 2.75% 730.56% -0.24% -55.97% -1.83% -4.07%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
77.19% 72.81% 74.04% 73.58% 69.20% 66.66% 64.27% 68.01% 69.09% 70.80% 70.76%
EBITDA Margin
-29.48% -65.80% -44.76% -24.13% -8.44% -6.35% -39.20% -2.01% -556.18% 4.02% -25.07%
Operating Margin
-34.81% -72.09% -50.88% -32.32% -16.95% -14.54% -46.29% -13.07% -567.27% -9.55% -39.73%
EBIT Margin
-34.81% -72.09% -57.75% -38.37% -16.95% -14.48% -46.34% -12.82% -567.30% -9.38% -39.96%
Profit (Net Income) Margin
-39.14% -74.98% -60.26% -45.77% -23.23% -17.87% -44.35% -21.09% -567.53% -8.47% -38.97%
Tax Burden Percent
102.33% 100.06% 100.69% 99.79% 100.12% 90.32% 84.23% 111.47% 99.97% 100.35% 100.76%
Interest Burden Percent
109.89% 103.94% 103.64% 119.54% 136.85% 136.65% 113.62% 147.64% 100.07% 89.96% 96.76%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-64.93% -77.82% -31.65% -12.37% -6.23% -5.89% -4.05% -1.13% -98.84% -6.06% -31.41%
ROIC Less NNEP Spread (ROIC-NNEP)
-2.37% -48.95% 14.25% -181.99% -453.93% 67.79% -45.71% -49.30% -931.96% -14.39% -109.53%
Return on Net Nonoperating Assets (RNNOA)
0.91% 27.76% -4.60% -14.67% -6.13% -3.86% -1.70% -1.56% -50.01% -3.46% -21.06%
Return on Equity (ROE)
-64.01% -50.06% -36.25% -27.04% -12.35% -9.75% -5.74% -2.69% -148.85% -9.51% -52.46%
Cash Return on Invested Capital (CROIC)
-264.93% -147.62% -133.96% -114.18% -44.55% -7.26% -182.08% 0.01% 39.87% 0.17% 13.28%
Operating Return on Assets (OROA)
-16.50% -34.69% -26.67% -15.87% -6.02% -5.12% -5.24% -1.47% -123.68% -5.59% -25.97%
Return on Assets (ROA)
-18.55% -36.08% -27.83% -18.93% -8.25% -6.31% -5.01% -2.42% -123.73% -5.04% -25.32%
Return on Common Equity (ROCE)
81.21% -23.98% -36.25% -27.04% -12.35% -9.75% -5.74% -2.69% -148.85% -9.51% -52.46%
Return on Equity Simple (ROE_SIMPLE)
25.23% -32.49% -32.15% -19.11% -9.58% -9.75% -3.05% -2.67% -591.90% -9.47% -67.15%
Net Operating Profit after Tax (NOPAT)
-11 -39 -44 -53 -50 -56 -354 -186 -9,557 -174 -715
NOPAT Margin
-24.36% -50.46% -35.62% -22.62% -11.87% -10.18% -32.40% -9.15% -397.09% -6.69% -27.81%
Net Nonoperating Expense Percent (NNEP)
-62.56% -28.87% -45.90% 169.62% 447.71% -73.68% 41.67% 48.17% 833.12% 8.33% 78.12%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -246.25% -4.45% -23.31%
Cost of Revenue to Revenue
22.81% 27.19% 25.96% 26.42% 30.80% 33.34% 35.73% 31.99% 30.91% 29.20% 29.24%
SG&A Expenses to Revenue
67.22% 78.77% 60.74% 50.48% 42.13% 41.45% 60.40% 33.88% 28.13% 26.07% 24.93%
R&D to Revenue
17.40% 18.36% 17.71% 14.77% 13.01% 11.68% 15.08% 15.34% 13.86% 13.39% 11.96%
Operating Expenses to Revenue
111.99% 144.90% 124.92% 105.90% 86.15% 81.20% 110.57% 81.08% 636.36% 80.35% 110.49%
Earnings before Interest and Taxes (EBIT)
-15 -56 -71 -90 -71 -80 -507 -261 -13,654 -244 -1,027
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -51 -55 -56 -35 -35 -429 -41 -13,386 105 -644
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 3.87 3.29 3.55 3.43 5.98 1.82 0.92 1.66 1.53 1.05
Price to Tangible Book Value (P/TBV)
0.00 6.46 42.64 0.00 121.82 142.61 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 8.92 6.17 8.51 8.32 10.95 26.50 7.23 1.59 1.37 0.61
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 8.56 3.52 3.21 3.59 6.24 1.79 0.92 1.51 1.45 1.04
Enterprise Value to Revenue (EV/Rev)
0.00 7.49 5.99 8.87 8.16 10.86 27.12 7.39 1.86 1.55 0.72
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 38.48 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 201.15 0.00 77.47 23.69 11.50 6.27
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 12,776.34 1.16 807.89 6.09
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.49 0.15 0.19 0.37 0.41 0.46 0.09 0.08 0.68 0.68 1.06
Long-Term Debt to Equity
0.47 0.14 0.18 0.37 0.41 0.46 0.09 0.08 0.68 0.68 0.69
Financial Leverage
-0.39 -0.57 -0.32 0.08 0.01 -0.06 0.04 0.03 0.05 0.24 0.19
Leverage Ratio
1.73 1.39 1.30 1.43 1.50 1.54 1.15 1.11 1.20 1.89 2.07
Compound Leverage Factor
1.90 1.44 1.35 1.71 2.05 2.11 1.30 1.64 1.20 1.70 2.00
Debt to Total Capital
32.71% 12.91% 16.14% 27.06% 29.04% 31.46% 8.45% 7.10% 40.54% 40.47% 51.36%
Short-Term Debt to Total Capital
1.05% 0.61% 0.73% 0.00% 0.00% 0.00% 0.25% 0.00% 0.00% 0.00% 17.97%
Long-Term Debt to Total Capital
31.65% 12.30% 15.41% 27.06% 29.04% 31.46% 8.20% 7.10% 40.54% 40.47% 33.39%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
152.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-85.37% 87.09% 83.86% 72.94% 70.96% 68.54% 91.55% 92.90% 59.46% 59.53% 48.64%
Debt to EBITDA
-2.02 -0.52 -0.81 -3.68 -11.76 -13.24 -3.42 -29.95 -0.12 15.12 -2.44
Net Debt to EBITDA
1.60 2.18 0.39 -1.51 1.81 1.47 -1.58 -8.06 -0.05 4.38 -0.43
Long-Term Debt to EBITDA
-1.95 -0.50 -0.77 -3.68 -11.76 -13.24 -3.32 -29.95 -0.12 15.12 -1.59
Debt to NOPAT
-2.44 -0.68 -1.01 -3.93 -8.36 -8.27 -4.13 -6.59 -0.16 -9.09 -2.20
Net Debt to NOPAT
1.94 2.84 0.49 -1.61 1.29 0.92 -1.91 -1.77 -0.07 -2.63 -0.39
Long-Term Debt to NOPAT
-2.36 -0.65 -0.97 -3.93 -8.36 -8.27 -4.01 -6.59 -0.16 -9.09 -1.43
Altman Z-Score
0.00 7.54 5.19 4.05 4.16 6.28 9.23 5.27 -13.27 -3.12 -5.98
Noncontrolling Interest Sharing Ratio
226.87% 52.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.28 8.43 3.93 3.87 8.53 6.52 3.19 3.70 3.29 3.54 1.77
Quick Ratio
5.16 8.31 3.78 3.70 8.36 6.37 2.87 3.22 2.82 3.19 1.61
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-43 -74 -186 -487 -355 -69 -15,955 1.18 3,855 4.98 302
Operating Cash Flow to CapEx
-1,062.58% -751.89% -2,460.86% -1,308.05% 0.00% 850.97% -205.48% 303.42% 109.57% 223.87% 236.74%
Free Cash Flow to Firm to Interest Expense
-28.87 -33.69 -71.74 -27.86 -13.59 -2.36 -231.14 0.01 175.69 0.22 12.70
Operating Cash Flow to Interest Expense
-7.58 -21.46 -20.04 -1.97 -0.19 1.02 -0.78 1.55 8.63 15.71 12.34
Operating Cash Flow Less CapEx to Interest Expense
-8.29 -24.31 -20.86 -2.12 -0.13 0.90 -1.15 1.04 0.75 8.69 7.13
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.47 0.48 0.46 0.41 0.36 0.35 0.11 0.11 0.22 0.60 0.65
Accounts Receivable Turnover
6.36 8.16 9.50 11.41 11.83 11.01 9.67 12.02 12.68 12.16 11.91
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.04 11.50 17.71 22.21
Fixed Asset Turnover
40.87 21.13 17.93 28.38 43.73 54.13 56.32 72.88 84.64 84.39 83.54
Accounts Payable Turnover
4.49 9.51 14.37 20.14 22.09 21.90 14.18 13.94 15.67 16.64 19.57
Days Sales Outstanding (DSO)
57.35 44.75 38.44 32.00 30.86 33.15 37.74 30.37 28.78 30.01 30.65
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 36.37 31.75 20.62 16.43
Days Payable Outstanding (DPO)
81.24 38.36 25.40 18.12 16.52 16.66 25.73 26.18 23.29 21.93 18.65
Cash Conversion Cycle (CCC)
-23.89 6.38 13.04 13.87 14.34 16.49 12.01 40.55 37.23 28.70 28.44
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
33 68 209 644 949 962 16,563 16,375 2,963 2,784 1,767
Invested Capital Turnover
2.66 1.54 0.89 0.55 0.52 0.58 0.12 0.12 0.25 0.91 1.13
Increase / (Decrease) in Invested Capital
33 35 142 434 305 13 15,600 -187 -13,413 -179 -1,017
Enterprise Value (EV)
0.00 580 738 2,070 3,411 6,008 29,665 15,029 4,485 4,026 1,841
Market Capitalization
0.00 691 760 1,985 3,475 6,060 28,986 14,699 3,830 3,568 1,565
Book Value per Share
($34.41) $4.64 $5.02 $9.81 $14.45 $14.01 $109.57 $100.23 $14.25 $14.05 $8.66
Tangible Book Value per Share
($52.74) $2.78 $0.39 ($1.75) $0.41 $0.59 ($4.96) ($2.30) ($3.72) ($2.57) ($1.30)
Total Capital
79 205 275 766 1,428 1,479 17,349 17,271 3,881 3,908 3,065
Total Debt
26 26 44 207 415 465 1,465 1,226 1,573 1,582 1,574
Total Long-Term Debt
25 25 42 207 415 465 1,423 1,226 1,573 1,582 1,024
Net Debt
-21 -111 -21 85 -64 -52 679 330 655 458 276
Capital Expenditures (CapEx)
1.07 6.28 2.11 2.63 -1.52 3.51 26 64 173 156 124
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.43 -2.51 -2.16 -6.40 -8.24 -19 -17 -1.59 -2.56 -55 -25
Debt-free Net Working Capital (DFNWC)
45 135 64 116 470 498 770 894 916 1,068 1,273
Net Working Capital (NWC)
44 134 62 116 470 498 727 894 916 1,068 722
Net Nonoperating Expense (NNE)
6.43 19 30 54 47 43 131 243 4,102 46 287
Net Nonoperating Obligations (NNO)
-21 -111 -21 85 -64 -52 679 330 655 458 276
Total Depreciation and Amortization (D&A)
2.32 4.86 16 33 36 45 78 220 268 349 383
Debt-free, Cash-free Net Working Capital to Revenue
-3.28% -3.24% -1.76% -2.74% -1.97% -3.48% -1.56% -0.08% -0.11% -2.12% -0.98%
Debt-free Net Working Capital to Revenue
103.40% 174.25% 51.68% 49.69% 112.54% 89.97% 70.34% 44.00% 38.04% 41.06% 49.55%
Net Working Capital to Revenue
101.49% 172.64% 50.05% 49.69% 112.54% 89.97% 66.45% 44.00% 38.04% 41.06% 28.11%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($10.25) ($2.91) ($1.75) ($1.93) ($1.47) ($1.38) ($5.36) ($2.73) ($84.60) ($1.34) ($5.87)
Adjusted Weighted Average Basic Shares Outstanding
1.96M 38.56M 54.24M 61.73M 70.77M 73.01M 152.70M 156.94M 161.46M 164.58M 170.56M
Adjusted Diluted Earnings per Share
($10.25) ($2.91) ($1.75) ($1.93) ($1.47) ($1.38) ($5.36) ($2.73) ($84.60) ($1.34) ($5.87)
Adjusted Weighted Average Diluted Shares Outstanding
1.96M 38.56M 54.24M 61.73M 70.77M 73.01M 152.70M 156.94M 161.46M 164.58M 170.56M
Adjusted Basic & Diluted Earnings per Share
($10.25) ($2.91) ($1.75) ($1.93) ($1.47) ($1.38) ($5.36) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.96M 19.92M 42.33M 55.43M 65.84M 71.84M 90.51M 160.33M 162.62M 167.04M 173.67M
Normalized Net Operating Profit after Tax (NOPAT)
-9.55 -32 -36 -44 -46 -52 -293 -167 -159 -147 -146
Normalized NOPAT Margin
-21.94% -41.93% -29.32% -18.66% -11.05% -9.34% -26.76% -8.23% -6.61% -5.66% -5.69%
Pre Tax Income Margin
-38.25% -74.93% -59.85% -45.87% -23.20% -19.78% -52.65% -18.92% -567.69% -8.44% -38.67%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-10.11 -25.37 -27.48 -5.12 -2.71 -2.73 -7.34 -2.09 -622.22 -10.96 -43.14
NOPAT to Interest Expense
-7.07 -17.76 -16.95 -3.02 -1.90 -1.92 -5.14 -1.49 -435.53 -7.81 -30.02
EBIT Less CapEx to Interest Expense
-10.82 -28.22 -28.29 -5.27 -2.66 -2.85 -7.72 -2.60 -630.10 -17.97 -48.35
NOPAT Less CapEx to Interest Expense
-7.79 -20.61 -17.76 -3.17 -1.84 -2.04 -5.51 -2.00 -443.40 -14.83 -35.23
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-2.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Teladoc Health

This table displays calculated financial ratios and metrics derived from Teladoc Health's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
17.20% 15.06% 11.30% 10.13% 7.99% 3.58% 2.68% -1.53% -2.99% -3.03%
EBITDA Growth
-33.79% -24,698.78% 100.01% 100.21% 485.51% 101.80% 1,920.65% -11,826.25% 63.70% -46.34%
EBIT Growth
-20.26% -9,016.52% 98.92% 97.68% 9.26% 99.12% -21.19% -1,071.45% 36.61% -65.62%
NOPAT Growth
-18.41% -9,109.86% 98.84% 97.69% 9.77% 99.08% -13.00% -1,074.05% 31.40% -37.44%
Net Income Growth
12.88% -34,584.31% 98.96% 97.90% 22.32% 99.24% -18.29% -1,185.22% 41.70% -67.56%
EPS Growth
15.09% -77,733.33% 98.99% 97.92% 22.22% 99.27% -16.67% -1,130.00% 45.71% -58.82%
Operating Cash Flow Growth
-17.72% -21.22% 141.44% 9.42% 67.56% 98.45% -32.20% -12.35% 4.33% -33.96%
Free Cash Flow Firm Growth
166.63% 6,693.44% 259.52% -49.13% -60.07% -98.56% -98.44% -89.43% -74.98% 536.70%
Invested Capital Growth
-59.01% -81.91% -70.24% -57.07% -57.86% -6.04% -5.73% -34.10% -35.04% -36.53%
Revenue Q/Q Growth
3.21% 4.30% -1.33% 3.68% 1.20% 0.04% -2.18% -0.57% -0.30% 0.00%
EBITDA Q/Q Growth
99.74% -47,406.15% 100.02% 883.70% 378.80% 121.88% -80.85% -5,808.58% 106.68% -27.26%
EBIT Q/Q Growth
97.63% -5,102.94% 98.11% 0.48% 7.43% 49.57% -160.83% -862.04% 94.99% -31.77%
NOPAT Q/Q Growth
97.68% -5,219.33% 97.98% 7.08% 9.66% 45.80% -148.35% -865.48% 94.72% -8.59%
Net Income Q/Q Growth
97.63% -5,085.46% 98.18% 5.85% 12.43% 49.38% -183.45% -922.93% 96.03% -45.48%
EPS Q/Q Growth
97.66% -5,088.89% 98.20% 4.76% 12.50% 51.43% -188.24% -904.08% 96.14% -42.11%
Operating Cash Flow Q/Q Growth
-31.85% 4.01% -79.93% 669.09% 4.37% 23.18% -93.14% 894.20% 24.23% -22.03%
Free Cash Flow Firm Q/Q Growth
28.39% 11.47% -35.91% -44.53% 0.76% -95.99% -30.50% 276.09% 138.50% 2.13%
Invested Capital Q/Q Growth
-0.74% -55.97% -0.81% -0.97% -2.56% -1.83% -0.48% -30.78% -3.95% -4.07%
Profitability Metrics
- - - - - - - - - -
Gross Margin
69.64% 70.38% 69.79% 70.79% 71.83% 70.72% 69.89% 70.73% 71.94% 70.50%
EBITDA Margin
-1.29% -586.13% 0.10% 0.97% 4.59% 10.19% 2.01% -115.63% 7.75% 5.64%
Operating Margin
-11.73% -598.32% -12.25% -10.98% -9.80% -5.31% -13.48% -130.93% -6.93% -7.53%
EBIT Margin
-11.99% -598.05% -11.47% -11.01% -10.07% -5.08% -13.54% -131.02% -6.58% -8.67%
Profit (Net Income) Margin
-12.02% -597.46% -11.00% -9.99% -8.64% -4.37% -12.67% -130.39% -5.20% -7.56%
Tax Burden Percent
98.43% 99.95% 100.99% 98.56% 95.83% 113.85% 103.40% 100.47% 102.40% 100.49%
Interest Burden Percent
101.84% 99.95% 94.95% 92.04% 89.54% 75.65% 90.52% 99.06% 77.07% 86.71%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-1.65% -104.25% -3.31% -4.02% -3.70% -3.37% -8.66% -99.07% -5.37% -5.95%
ROIC Less NNEP Spread (ROIC-NNEP)
-5.86% -335.61% -5.52% -6.31% -5.63% -4.15% -12.36% -147.35% -5.87% -9.95%
Return on Net Nonoperating Assets (RNNOA)
-0.29% -18.01% -0.67% -0.99% -0.82% -1.00% -3.05% -40.00% -1.35% -1.91%
Return on Equity (ROE)
-1.94% -122.26% -3.97% -5.00% -4.52% -4.36% -11.71% -139.07% -6.73% -7.86%
Cash Return on Invested Capital (CROIC)
23.95% 39.87% 31.14% 21.54% 22.43% 0.17% -0.44% 11.30% 12.33% 13.28%
Operating Return on Assets (OROA)
-2.16% -130.38% -3.68% -4.49% -4.18% -3.03% -8.22% -87.21% -4.34% -5.64%
Return on Assets (ROA)
-2.17% -130.25% -3.53% -4.07% -3.59% -2.61% -7.69% -86.79% -3.42% -4.91%
Return on Common Equity (ROCE)
-1.94% -122.26% -3.97% -5.00% -4.52% -4.36% -11.71% -139.07% -6.73% -7.86%
Return on Equity Simple (ROE_SIMPLE)
-162.91% 0.00% -307.88% -175.06% -174.43% 0.00% -10.18% -66.94% -65.11% 0.00%
Net Operating Profit after Tax (NOPAT)
-50 -2,671 -54 -50 -45 -25 -61 -589 -31 -34
NOPAT Margin
-8.21% -418.83% -8.58% -7.69% -6.86% -3.72% -9.44% -91.65% -4.85% -5.27%
Net Nonoperating Expense Percent (NNEP)
4.22% 231.35% 2.21% 2.30% 1.93% 0.78% 3.70% 48.28% 0.50% 4.00%
Return On Investment Capital (ROIC_SIMPLE)
- -68.82% - - - -0.63% - - - -1.10%
Cost of Revenue to Revenue
30.36% 29.62% 30.21% 29.21% 28.17% 29.28% 30.11% 29.27% 28.06% 29.50%
SG&A Expenses to Revenue
27.27% 27.62% 26.80% 27.49% 25.45% 24.59% 25.70% 24.90% 25.25% 23.84%
R&D to Revenue
13.84% 13.00% 13.82% 13.38% 12.77% 13.62% 12.60% 11.95% 11.30% 11.98%
Operating Expenses to Revenue
81.37% 668.70% 82.04% 81.78% 81.64% 76.03% 83.38% 201.66% 78.87% 78.03%
Earnings before Interest and Taxes (EBIT)
-73 -3,814 -72 -72 -67 -34 -87 -842 -42 -56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.87 -3,738 0.64 6.34 30 67 13 -743 50 36
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.68 1.66 1.84 1.81 1.34 1.53 1.09 1.10 1.04 1.05
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.76 1.59 1.70 1.64 1.19 1.37 0.95 0.64 0.61 0.61
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.71 1.51 1.65 1.64 1.27 1.45 1.08 1.08 1.03 1.04
Enterprise Value to Revenue (EV/Rev)
2.05 1.86 1.97 1.88 1.40 1.55 1.14 0.80 0.74 0.72
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 38.48 24.93 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
23.07 23.69 20.75 19.59 12.64 11.50 8.62 6.22 5.64 6.27
Enterprise Value to Free Cash Flow (EV/FCFF)
1.72 1.16 2.44 4.56 3.36 807.89 0.00 7.60 6.61 6.09
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.26 0.68 0.67 0.69 0.69 0.68 0.69 1.05 1.05 1.06
Long-Term Debt to Equity
0.26 0.68 0.67 0.69 0.69 0.68 0.69 0.68 0.68 0.69
Financial Leverage
0.05 0.05 0.12 0.16 0.15 0.24 0.25 0.27 0.23 0.19
Leverage Ratio
1.17 1.20 1.35 1.48 1.49 1.89 1.88 2.06 2.07 2.07
Compound Leverage Factor
1.19 1.20 1.28 1.36 1.33 1.43 1.71 2.05 1.59 1.80
Debt to Total Capital
20.65% 40.54% 40.14% 40.68% 40.66% 40.47% 40.83% 51.23% 51.14% 51.36%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.88% 17.85% 17.97%
Long-Term Debt to Total Capital
20.65% 40.54% 40.14% 40.68% 40.66% 40.47% 40.83% 33.35% 33.30% 33.39%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
79.35% 59.46% 59.86% 59.32% 59.34% 59.53% 59.17% 48.77% 48.86% 48.64%
Debt to EBITDA
-0.16 -0.12 -0.23 -0.42 -0.43 15.12 13.21 -2.51 -2.59 -2.44
Net Debt to EBITDA
-0.07 -0.05 -0.10 -0.16 -0.15 4.38 4.03 -0.66 -0.55 -0.43
Long-Term Debt to EBITDA
-0.16 -0.12 -0.23 -0.42 -0.43 15.12 13.21 -1.63 -1.68 -1.59
Debt to NOPAT
-0.23 -0.16 -0.31 -0.56 -0.56 -9.09 -8.73 -2.19 -2.24 -2.20
Net Debt to NOPAT
-0.10 -0.07 -0.13 -0.22 -0.19 -2.63 -2.66 -0.58 -0.47 -0.39
Long-Term Debt to NOPAT
-0.23 -0.16 -0.31 -0.56 -0.56 -9.09 -8.73 -1.43 -1.46 -1.43
Altman Z-Score
-0.35 -5.80 -2.87 -2.89 -3.19 -2.96 -3.38 -5.76 -5.03 -5.07
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
3.13 3.29 3.37 3.45 3.45 3.54 3.82 1.66 1.73 1.77
Quick Ratio
2.68 2.82 2.90 3.06 3.07 3.19 3.37 1.48 1.56 1.61
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
9,637 10,742 6,884 3,818 3,848 154 107 404 963 983
Operating Cash Flow to CapEx
145.87% 121.63% 28.84% 276.68% 280.50% 356.32% 25.12% 319.60% 353.71% 289.78%
Free Cash Flow to Firm to Interest Expense
1,567.17 2,259.97 1,307.96 654.40 681.46 27.88 19.00 0.00 170.07 0.00
Operating Cash Flow to Interest Expense
10.25 13.79 2.50 17.34 18.70 23.49 1.58 0.00 19.47 0.00
Operating Cash Flow Less CapEx to Interest Expense
3.22 2.45 -6.17 11.07 12.04 16.90 -4.71 0.00 13.96 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.18 0.22 0.32 0.41 0.42 0.60 0.61 0.67 0.66 0.65
Accounts Receivable Turnover
12.24 12.68 12.13 12.03 12.66 12.16 12.18 12.04 12.39 11.91
Inventory Turnover
12.56 11.50 12.83 16.01 15.86 17.71 19.58 22.10 20.73 22.21
Fixed Asset Turnover
85.58 84.64 84.89 87.58 85.76 84.39 88.28 87.38 85.02 83.54
Accounts Payable Turnover
13.85 15.67 17.37 13.67 15.61 16.64 20.04 21.11 23.69 19.57
Days Sales Outstanding (DSO)
29.83 28.78 30.10 30.33 28.83 30.01 29.98 30.33 29.45 30.65
Days Inventory Outstanding (DIO)
29.07 31.75 28.45 22.79 23.01 20.62 18.64 16.51 17.61 16.43
Days Payable Outstanding (DPO)
26.36 23.29 21.02 26.69 23.38 21.93 18.21 17.29 15.41 18.65
Cash Conversion Cycle (CCC)
32.54 37.23 37.53 26.43 28.47 28.70 30.40 29.55 31.65 28.44
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
6,729 2,963 2,939 2,910 2,836 2,784 2,770 1,918 1,842 1,767
Invested Capital Turnover
0.20 0.25 0.39 0.52 0.54 0.91 0.92 1.08 1.11 1.13
Increase / (Decrease) in Invested Capital
-9,687 -13,413 -6,938 -3,869 -3,893 -179 -168 -992 -994 -1,017
Enterprise Value (EV)
4,774 4,485 4,859 4,759 3,608 4,026 2,981 2,074 1,906 1,841
Market Capitalization
4,098 3,830 4,212 4,144 3,066 3,568 2,500 1,659 1,572 1,565
Book Value per Share
$37.44 $14.25 $14.09 $14.02 $13.91 $14.05 $13.65 $8.86 $8.81 $8.66
Tangible Book Value per Share
($4.01) ($3.72) ($3.68) ($3.43) ($3.08) ($2.57) ($2.38) ($1.94) ($1.59) ($1.30)
Total Capital
7,628 3,881 3,827 3,869 3,866 3,908 3,868 3,080 3,086 3,065
Total Debt
1,576 1,573 1,536 1,574 1,572 1,582 1,580 1,578 1,578 1,574
Total Long-Term Debt
1,576 1,573 1,536 1,574 1,572 1,582 1,580 1,027 1,027 1,024
Net Debt
676 655 648 615 542 458 482 416 334 276
Capital Expenditures (CapEx)
43 54 46 37 38 37 36 28 31 30
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-23 -2.56 17 -21 -46 -55 -0.51 4.27 -16 -25
Debt-free Net Working Capital (DFNWC)
876 916 905 938 984 1,068 1,097 1,167 1,228 1,273
Net Working Capital (NWC)
876 916 905 938 984 1,068 1,097 616 677 722
Net Nonoperating Expense (NNE)
23 1,139 15 15 12 4.33 21 249 2.20 15
Net Nonoperating Obligations (NNO)
676 655 648 615 542 458 482 416 334 276
Total Depreciation and Amortization (D&A)
65 76 73 78 97 101 101 99 92 92
Debt-free, Cash-free Net Working Capital to Revenue
-1.01% -0.11% 0.68% -0.83% -1.79% -2.12% -0.02% 0.16% -0.61% -0.98%
Debt-free Net Working Capital to Revenue
37.71% 38.04% 36.64% 37.05% 38.16% 41.06% 41.90% 44.71% 47.42% 49.55%
Net Working Capital to Revenue
37.71% 38.04% 36.64% 37.05% 38.16% 41.06% 41.90% 23.60% 26.15% 28.11%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.45) ($23.35) ($0.42) ($0.40) ($0.35) ($0.17) ($0.49) ($4.92) ($0.19) ($0.27)
Adjusted Weighted Average Basic Shares Outstanding
161.73M 161.46M 162.92M 164.17M 165.12M 164.58M 167.73M 170.23M 171.50M 170.56M
Adjusted Diluted Earnings per Share
($0.45) ($23.35) ($0.42) ($0.40) ($0.35) ($0.17) ($0.49) ($4.92) ($0.19) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding
161.73M 161.46M 162.92M 164.17M 165.12M 164.58M 167.73M 170.23M 171.50M 170.56M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
161.93M 162.62M 163.67M 164.95M 165.56M 167.04M 169.59M 171.22M 172.17M 173.67M
Normalized Net Operating Profit after Tax (NOPAT)
-47 -23 -44 -41 -41 -21 -54 -34 -28 -30
Normalized NOPAT Margin
-7.61% -3.55% -7.01% -6.33% -6.20% -3.17% -8.35% -5.36% -4.41% -4.61%
Pre Tax Income Margin
-12.21% -597.75% -10.89% -10.14% -9.02% -3.84% -12.26% -129.78% -5.07% -7.52%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-11.92 -802.40 -13.72 -12.31 -11.78 -6.06 -15.49 0.00 -7.45 0.00
NOPAT to Interest Expense
-8.17 -561.94 -10.25 -8.59 -8.02 -4.43 -10.80 0.00 -5.49 0.00
EBIT Less CapEx to Interest Expense
-18.95 -813.74 -22.39 -18.58 -18.45 -12.65 -21.77 0.00 -12.95 0.00
NOPAT Less CapEx to Interest Expense
-15.19 -573.28 -18.92 -14.86 -14.69 -11.03 -17.08 0.00 -10.99 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Teladoc Health's Financials

When does Teladoc Health's fiscal year end?

According to the most recent income statement we have on file, Teladoc Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Teladoc Health's net income changed over the last 10 years?

Teladoc Health's net income appears to be on an upward trend, with a most recent value of -$1.00 billion in 2024, rising from -$17.04 million in 2014. The previous period was -$220.37 million in 2023.

What is Teladoc Health's operating income?
Teladoc Health's total operating income in 2024 was -$1.02 billion, based on the following breakdown:
  • Total Gross Profit: $1.82 billion
  • Total Operating Expenses: $2.84 billion
How has Teladoc Health revenue changed over the last 10 years?

Over the last 10 years, Teladoc Health's total revenue changed from $43.53 million in 2014 to $2.57 billion in 2024, a change of 5,803.3%.

How much debt does Teladoc Health have?

Teladoc Health's total liabilities were at $2.03 billion at the end of 2024, a 2.0% decrease from 2023, and a 5,146.2% increase since 2014.

How much cash does Teladoc Health have?

In the past 10 years, Teladoc Health's cash and equivalents has ranged from $42.82 million in 2017 to $1.30 billion in 2024, and is currently $1.30 billion as of their latest financial filing in 2024.

How has Teladoc Health's book value per share changed over the last 10 years?

Over the last 10 years, Teladoc Health's book value per share changed from -34.41 in 2014 to 8.66 in 2024, a change of -125.2%.



This page (NYSE:TDOC) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners